Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Mellitus Patients Not Achieving Glycemic Targets on Basal Insulin With/Without Anti-Hyperglycemic Agents is a NA clinical asset sponsored by Calibra Medical, Inc. in Diabetes Mellitus, Type 2. SEO and diligence focus: Bolus Insulin Patch (Calibra Finesse), Insulin Pen (Novo-Nordisk FlexPen®), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.